Jost B. Jonas
Research Subjects
Jost B. Jonas has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
I Kreissig
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Germany
6 shared publicationsIngrid Kreissig
5 shared publicationsR F Degenring
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Germany
5 shared publicationsImren Akkoyun
3 shared publicationsBernd A. Kamppeter
2 shared publicationsBjörn Harder
2 shared publications
Latest Publications
- 13 October 2008
- Published by S. Karger AG in Ophthalmic Research
- Vol. 41 (1) , 21-27
Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration
Background: To compare an intravitreal high-dose injection of triamcinolone acetonide with an intravitreal injection of bevacizumab for the treatment of progressive exudative age-related macular degeneration (AMD). Method: The comparative nonrandomized retrospective clinical interventional study included 305 patients with progressive AMD, divided into a bevacizumab group of 36 patients (1.5 mg bevacizumab) and a triamcinolone group of 269 patients (about 20 mg triamcinolone). All patients were consecutively included, in the first phase of the study for triamcinolone, and in the second phase of the study for bevacizumab. The mean follow-up was 8.5 ± 6.8 months (2–35.7 months). Results: In the bevacizumab group, best visual acuity increased significantly (p < 0.001) by 3.2 ± 3.4 Snellen lines, with 25 (69%) eyes and 21 (58%) eyes, improving by at least 2 and 3 Snellen lines, respectively. In the triamcinolone group, the visual acuity change was not statistically significant for any specific follow-up examination within the first 3 months. The maximal increase in visual acuity, the visual acuity change at 2 months after injection and the percentage of patients with an improvement by at least 2 and 3 Snellen lines were significantly (p < 0.001) higher in the bevacizumab group than in the triamcinolone group. Intraocular pressure increased significantly (p < 0.001) in the triamcinolone group and did not change significantly (p = 0.47) in the bevacizumab group. Conclusion: In exudative AMD, intravitreal bevacizumab (1.5 mg) compared with intravitreal triamcinolone acetonide (about 20 mg) results in a higher improvement of visual acuity and does not markedly influence intraocular pressure within 2 months after injection.
- 13 October 2008
- Published by S. Karger AG in Ophthalmic Research
- Vol. 41 (1) , 21-27
Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration
Background: To compare an intravitreal high-dose injection of triamcinolone acetonide with an intravitreal injection of bevacizumab for the treatment of progressive exudative age-related macular degeneration (AMD). Method: The comparative nonrandomized retrospective clinical interventional study included 305 patients with progressive AMD, divided into a bevacizumab group of 36 patients (1.5 mg bevacizumab) and a triamcinolone group of 269 patients (about 20 mg triamcinolone). All patients were consecutively included, in the first phase of the study for triamcinolone, and in the second phase of the study for bevacizumab. The mean follow-up was 8.5 ± 6.8 months (2–35.7 months). Results: In the bevacizumab group, best visual acuity increased significantly (p < 0.001) by 3.2 ± 3.4 Snellen lines, with 25 (69%) eyes and 21 (58%) eyes, improving by at least 2 and 3 Snellen lines, respectively. In the triamcinolone group, the visual acuity change was not statistically significant for any specific follow-up examination within the first 3 months. The maximal increase in visual acuity, the visual acuity change at 2 months after injection and the percentage of patients with an improvement by at least 2 and 3 Snellen lines were significantly (p < 0.001) higher in the bevacizumab group than in the triamcinolone group. Intraocular pressure increased significantly (p < 0.001) in the triamcinolone group and did not change significantly (p = 0.47) in the bevacizumab group. Conclusion: In exudative AMD, intravitreal bevacizumab (1.5 mg) compared with intravitreal triamcinolone acetonide (about 20 mg) results in a higher improvement of visual acuity and does not markedly influence intraocular pressure within 2 months after injection.
- 16 November 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (12) , 1711-1712
Decreased retinal vein diameter after intravitreal triamcinolone for retinal vein occlusions
The comparative non-randomized clinical interventional investigation included a study group of 21 patients (21 eyes) with central retinal vein occlusion …
- 16 November 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (12) , 1711-1712
Decreased retinal vein diameter after intravitreal triamcinolone for retinal vein occlusions
The comparative non-randomized clinical interventional investigation included a study group of 21 patients (21 eyes) with central retinal vein occlusion …
- 1 May 2006
- Published by Elsevier in Ophthalmology
- Vol. 113 (5) , 800-804
Repeated Intravitreal High-Dosage Injections of Triamcinolone Acetonide for Diffuse Diabetic Macular Edema
- 1 May 2006
- Published by Elsevier in Ophthalmology
- Vol. 113 (5) , 800-804
Repeated Intravitreal High-Dosage Injections of Triamcinolone Acetonide for Diffuse Diabetic Macular Edema
- 1 January 2006
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 16 (1) , 30-32
Cataract Surgery under Systemic Anticoagulant Therapy with Coumarin
To evaluate clinical outcome of cataract surgery under systemic anticoagulant therapy using coumarin. This clinical interventional comparative nonrandomized study included 441 patients (441 eyes) consecutively undergoing standard phacoemulsification with clear cornea incision and topical anesthesia. The study group consisted of 21 (4.8%) patients for whom systemic coumarin therapy was continued despite surgery. The control group included 420 patients without anticoagulant coumarin therapy prior to surgery. Study group and control group did not vary significantly in age, preoperative visual acuity, axial length, refractive error, preoperative intraocular pressure, or surgeon. Frequency of intraoperative or postoperative hemorrhages, intraoperative complications such as posterior capsule rupture, postoperative visual acuity, and intraocular pressure did no vary significantly (p>0.30) between study group and control group. For patients under systemic coumarin therapy, the rate of surgical complications may not markedly be increased compared to patients without coumarin therapy, when standard phacoemulsification with clear cornea incisions is performed with topical anesthesia. Systemic coumarin therapy does not have to be stopped prior to cataract surgery.
- 1 January 2006
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 16 (1) , 30-32
Cataract Surgery under Systemic Anticoagulant Therapy with Coumarin
To evaluate clinical outcome of cataract surgery under systemic anticoagulant therapy using coumarin. This clinical interventional comparative nonrandomized study included 441 patients (441 eyes) consecutively undergoing standard phacoemulsification with clear cornea incision and topical anesthesia. The study group consisted of 21 (4.8%) patients for whom systemic coumarin therapy was continued despite surgery. The control group included 420 patients without anticoagulant coumarin therapy prior to surgery. Study group and control group did not vary significantly in age, preoperative visual acuity, axial length, refractive error, preoperative intraocular pressure, or surgeon. Frequency of intraoperative or postoperative hemorrhages, intraoperative complications such as posterior capsule rupture, postoperative visual acuity, and intraocular pressure did no vary significantly (p>0.30) between study group and control group. For patients under systemic coumarin therapy, the rate of surgical complications may not markedly be increased compared to patients without coumarin therapy, when standard phacoemulsification with clear cornea incisions is performed with topical anesthesia. Systemic coumarin therapy does not have to be stopped prior to cataract surgery.
- 1 May 2005
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 15 (3) , 329-335
Cataract Surgery Combined with Intravitreal Injection of Triamcinolone Acetonide
Purpose: To evaluate whether the addition of cataract surgery to an intravitreal injection of triamcinolone acetonide markedly increases frequency and spectrum of complications. Methods: The comparative nonrandomized clinical interventional investigation included a study group of 60 eyes (56 patients) undergoing cataract surgery and additionally receiving an intravitreal injection of about 20 mg of triamcinolone acetonide and a triamcinolone control group of 290 eyes (262 patients) that consecutively received an intravitreal injection of about 20 mg triamcinolone acetonide without cataract surgery. Reasons for intravitreal injection of triamcinolone acetonide were exudative age-related macular degeneration (n = 228; 65%), diffuse diabetic macular edema (n = 94; 27%), central retinal vein occlusion (n = 17; 5%), and branch retinal vein occlusion (n = 11; 3%). Mean follow-up was 8.6±6.8 months. A second control group included 1068 patients (1068 eyes) who consecutively underwent routine cataract surgery without intravitreal injection. Results: Study group and triamcinolone control group did not vary significantly in best visual acuity during follow-up (p=0.08), final visual acuity at the end of follow-up (p=0.30), maximal intraocular pressure during follow-up (p=0.99), frequency of an intraocular pressure higher than 21 mmHg (p=0.66), and intraocular pressure at the end of follow-up (p=0.06). Postoperative infectious endophthalmitis, wound leakage or other corneal wound healing problems, persisting corneal endothelial decompensation, rhegmatogenous retinal detachment, marked postoperative pain, or a clinically significant decentration of the intraocular lens were not observed. Study group and the non-triamcinolone control group did not vary significantly in the rate of posterior lens capsule rupture (p=0.11), postoperative infectious endophthalmitis, and persisting postoperative corneal endothelial decompensation. Conclusions: The addition of cataract surgery to an intravitreal injection of triamcinolone acetonide may not markedly increase amount and frequency of side effects and complications of intravitreal triamcinolone acetonide. No safe conclusions can be reached regarding differences in frequency of postoperative infectious endophthalmitis.
- 1 May 2005
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 15 (3) , 329-335
Cataract Surgery Combined with Intravitreal Injection of Triamcinolone Acetonide
Purpose: To evaluate whether the addition of cataract surgery to an intravitreal injection of triamcinolone acetonide markedly increases frequency and spectrum of complications. Methods: The comparative nonrandomized clinical interventional investigation included a study group of 60 eyes (56 patients) undergoing cataract surgery and additionally receiving an intravitreal injection of about 20 mg of triamcinolone acetonide and a triamcinolone control group of 290 eyes (262 patients) that consecutively received an intravitreal injection of about 20 mg triamcinolone acetonide without cataract surgery. Reasons for intravitreal injection of triamcinolone acetonide were exudative age-related macular degeneration (n = 228; 65%), diffuse diabetic macular edema (n = 94; 27%), central retinal vein occlusion (n = 17; 5%), and branch retinal vein occlusion (n = 11; 3%). Mean follow-up was 8.6±6.8 months. A second control group included 1068 patients (1068 eyes) who consecutively underwent routine cataract surgery without intravitreal injection. Results: Study group and triamcinolone control group did not vary significantly in best visual acuity during follow-up (p=0.08), final visual acuity at the end of follow-up (p=0.30), maximal intraocular pressure during follow-up (p=0.99), frequency of an intraocular pressure higher than 21 mmHg (p=0.66), and intraocular pressure at the end of follow-up (p=0.06). Postoperative infectious endophthalmitis, wound leakage or other corneal wound healing problems, persisting corneal endothelial decompensation, rhegmatogenous retinal detachment, marked postoperative pain, or a clinically significant decentration of the intraocular lens were not observed. Study group and the non-triamcinolone control group did not vary significantly in the rate of posterior lens capsule rupture (p=0.11), postoperative infectious endophthalmitis, and persisting postoperative corneal endothelial decompensation. Conclusions: The addition of cataract surgery to an intravitreal injection of triamcinolone acetonide may not markedly increase amount and frequency of side effects and complications of intravitreal triamcinolone acetonide. No safe conclusions can be reached regarding differences in frequency of postoperative infectious endophthalmitis.
- 1 April 2005
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 16 (2) , 84-88
Clinical implications of peripapillary atrophy in glaucoma
To elucidate peripapillary atrophy in glaucomatous optic neuropathy; its ranking in the morphologic diagnosis of the glaucoma, and its value for the differentiation of various types of chronic open-angle glaucoma, for the separation of glaucomatous eyes from nonglaucomatous eyes, and for the detection of progression of glaucoma. Recent studies showed an association of peripapillary atrophy with glaucoma and the eventual development of glaucomatous disc hemorrhages independent of a small neuroretinal rim area, and an association between increasing peripapillary atrophy and progressive glaucoma. A ranking of optic disc parameters to detect glaucomatous damage revealed that the alpha and beta zones of peripapillary atrophy, compared with neuroretinal rim parameters, are less useful. Pseudoexfoliation syndrome without glaucoma is not a risk factor for peripapillary atrophy. In arteritic anterior ischemic optic neuropathy, peripapillary atrophy does not enlarge. Peripapillary atrophy does not differ markedly between Europeans and South Indians. In contrast to the position of the central retinal vessel trunk, the presence and position of cilioretinal arteries do not markedly influence the progression of peripapillary atrophy in glaucoma. Peripapillary chorioretinal atrophy is one among several morphologic variables to detect glaucomatous abnormalities. Ranking optic disc variables for the detection of glaucomatous optic nerve damage, peripapillary atrophy is a variable of second order. It is useful for the differentiation of various types of chronic open-angle glaucomas. In contrast to glaucomatous eyes, eyes with nonglaucomatous optic nerve atrophy, including eyes after arteritic anterior ischemic optic neuropathy, do not show an enlarged peripapillary atrophy.
- 1 April 2005
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 16 (2) , 84-88
Clinical implications of peripapillary atrophy in glaucoma
To elucidate peripapillary atrophy in glaucomatous optic neuropathy; its ranking in the morphologic diagnosis of the glaucoma, and its value for the differentiation of various types of chronic open-angle glaucoma, for the separation of glaucomatous eyes from nonglaucomatous eyes, and for the detection of progression of glaucoma. Recent studies showed an association of peripapillary atrophy with glaucoma and the eventual development of glaucomatous disc hemorrhages independent of a small neuroretinal rim area, and an association between increasing peripapillary atrophy and progressive glaucoma. A ranking of optic disc parameters to detect glaucomatous damage revealed that the alpha and beta zones of peripapillary atrophy, compared with neuroretinal rim parameters, are less useful. Pseudoexfoliation syndrome without glaucoma is not a risk factor for peripapillary atrophy. In arteritic anterior ischemic optic neuropathy, peripapillary atrophy does not enlarge. Peripapillary atrophy does not differ markedly between Europeans and South Indians. In contrast to the position of the central retinal vessel trunk, the presence and position of cilioretinal arteries do not markedly influence the progression of peripapillary atrophy in glaucoma. Peripapillary chorioretinal atrophy is one among several morphologic variables to detect glaucomatous abnormalities. Ranking optic disc variables for the detection of glaucomatous optic nerve damage, peripapillary atrophy is a variable of second order. It is useful for the differentiation of various types of chronic open-angle glaucomas. In contrast to glaucomatous eyes, eyes with nonglaucomatous optic nerve atrophy, including eyes after arteritic anterior ischemic optic neuropathy, do not show an enlarged peripapillary atrophy.
- Open Access
- 1 March 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (3) , 321-326
Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study
Aim: To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. Methods: Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the study group (97 eyes) received an intravitreal injection of 20–25 mg of triamcinolone acetonide and no other retinal treatment. Patients of the control group (69 eyes) received focal or panretinal laser treatment if indicated. Mean (standard deviation) follow up was 8.4 (SD 6.0) months (range 1.03–25.2 months). Results: Visual acuity (VA) increased significantly (pConclusions: Intravitreal triamcinolone acetonide can temporarily increase VA in some patients with diffuse diabetic macular oedema.
- 1 March 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (3) , 321-326
Open AccessDiffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study
Aim: To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. Methods: Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the study group (97 eyes) received an intravitreal injection of 20–25 mg of triamcinolone acetonide and no other retinal treatment. Patients of the control group (69 eyes) received focal or panretinal laser treatment if indicated. Mean (standard deviation) follow up was 8.4 (SD 6.0) months (range 1.03–25.2 months). Results: Visual acuity (VA) increased significantly (pConclusions: Intravitreal triamcinolone acetonide can temporarily increase VA in some patients with diffuse diabetic macular oedema.
- Open Access
- 1 January 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (1) , 122
Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema
The clinical interventional case series study included four patients with diffuse diabetic macular oedema who consecutively received a second intravitreal injection of about 20 mg triamcinolone acetonide 7.6 (SD 3.9) months (median, 6.7 months; range, 4.1–13.1 months) after the first injection, and for whom follow up was longer than 3 months. The second injection was carried out, since visual acuity had decreased again after an initial increase following the first intravitreal injection. Mean follow up after the second injection was 5.6 (SD 4.2) months (median 5.6 months; range 1–10.5 months). Mean age of the patients was 62.0 (5.0) years (range 56.8–67.8 years; median 61.7 years), refractive error ranged between a mean of −0.75 (SD 1.19) dioptres and +2.50 (1.38) dioptres. All patients were fully informed about the experimental character of the therapy and had signed an informed consent. The ethics committee of the university had approved the study. All patients received an intravitreal injection of about 20 mg triamcinolone acetonide in 0.2 ml Ringer’s solution as previously described in detail.4
- 1 January 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (1) , 122
Open AccessRepeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema
The clinical interventional case series study included four patients with diffuse diabetic macular oedema who consecutively received a second intravitreal injection of about 20 mg triamcinolone acetonide 7.6 (SD 3.9) months (median, 6.7 months; range, 4.1–13.1 months) after the first injection, and for whom follow up was longer than 3 months. The second injection was carried out, since visual acuity had decreased again after an initial increase following the first intravitreal injection. Mean follow up after the second injection was 5.6 (SD 4.2) months (median 5.6 months; range 1–10.5 months). Mean age of the patients was 62.0 (5.0) years (range 56.8–67.8 years; median 61.7 years), refractive error ranged between a mean of −0.75 (SD 1.19) dioptres and +2.50 (1.38) dioptres. All patients were fully informed about the experimental character of the therapy and had signed an informed consent. The ethics committee of the university had approved the study. All patients received an intravitreal injection of about 20 mg triamcinolone acetonide in 0.2 ml Ringer’s solution as previously described in detail.4
- Open Access
- 1 January 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (1) , 3
Optic nerve grey crescent
The optic nerve head has been defined as all areas inside the peripapillary scleral ring. Outside this ring in the parapapillary region, various features and abnormalities can be differentiated. In almost all eyes, the retinal pigment epithelium shows some histological irregularities close to the tip of Bruch’s membrane at the border of the optic disc. It is the histological equivalent of the alpha zone of parapapillary atrophy which is present in almost all normal eyes. It can usually better be detected at the temporal disc margin than in other parts of the parapapillary region. The beta zone of parapapillary atrophy, present in about 25% of normal eyes, and in a higher percentage of glaucomatous eyes, reflects a complete loss of retinal pigment epithelium cells and an almost complete loss of retinal photoreceptors. Other abnormalities or changes in the parapapillary region include a hypertrophy of the retinal pigment epithelium mainly at the temporal optic disc border in eyes with a so called conus pigmentosus of the optic nerve head; proliferations of the retinal pigment epithelium such as in retinochoroidal toxoplasmotic scars or after subretinal parapapillary haemorrhages; and melanocytic lesions of the choroid such as choroidal naevi or a malignant choroidal melanoma.1
- 1 January 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (1) , 3
Open AccessOptic nerve grey crescent
The optic nerve head has been defined as all areas inside the peripapillary scleral ring. Outside this ring in the parapapillary region, various features and abnormalities can be differentiated. In almost all eyes, the retinal pigment epithelium shows some histological irregularities close to the tip of Bruch’s membrane at the border of the optic disc. It is the histological equivalent of the alpha zone of parapapillary atrophy which is present in almost all normal eyes. It can usually better be detected at the temporal disc margin than in other parts of the parapapillary region. The beta zone of parapapillary atrophy, present in about 25% of normal eyes, and in a higher percentage of glaucomatous eyes, reflects a complete loss of retinal pigment epithelium cells and an almost complete loss of retinal photoreceptors. Other abnormalities or changes in the parapapillary region include a hypertrophy of the retinal pigment epithelium mainly at the temporal optic disc border in eyes with a so called conus pigmentosus of the optic nerve head; proliferations of the retinal pigment epithelium such as in retinochoroidal toxoplasmotic scars or after subretinal parapapillary haemorrhages; and melanocytic lesions of the choroid such as choroidal naevi or a malignant choroidal melanoma.1
- Open Access
- 1 December 2004
- Published by BMJ in British Journal of Ophthalmology
- Vol. 88 (12) , 1557-1562
Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Aim: To evaluate factors influencing change in visual acuity (VA) after intravitreal injection of triamcinolone acetonide as treatment of exudative age related macular degeneration (AMD). Methods: This prospective, interventional, comparative non-randomised clinical case series study included 94 patients (99 eyes) showing progressive exudative AMD with occult (n = 61 eyes), minimally classic (n = 18), predominantly classic (n = 1), or totally classic (n = 8) subfoveal neovascularisation. Mean follow up was 8.5 (SD 4.7) months (median, 7.3 months; range 3.1–24.5 months). All patients received an intravitreal injection of 20–25 mg of triamcinolone acetonide. Results: An increase in best VA of at least one line on the Snellen charts was found in 63 (63.1%) eyes. Correspondingly, mean VA increased significantly (pConclusions: Gain in VA after intravitreal injection of 20–25 mg of triamcinolone acetonide is significantly and negatively correlated with preoperative VA. It is significantly larger in eyes with retinal pigment epithelium detachment than in eyes with minimally classic subfoveal neovascularisation.
- 1 December 2004
- Published by BMJ in British Journal of Ophthalmology
- Vol. 88 (12) , 1557-1562
Open AccessFactors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Aim: To evaluate factors influencing change in visual acuity (VA) after intravitreal injection of triamcinolone acetonide as treatment of exudative age related macular degeneration (AMD). Methods: This prospective, interventional, comparative non-randomised clinical case series study included 94 patients (99 eyes) showing progressive exudative AMD with occult (n = 61 eyes), minimally classic (n = 18), predominantly classic (n = 1), or totally classic (n = 8) subfoveal neovascularisation. Mean follow up was 8.5 (SD 4.7) months (median, 7.3 months; range 3.1–24.5 months). All patients received an intravitreal injection of 20–25 mg of triamcinolone acetonide. Results: An increase in best VA of at least one line on the Snellen charts was found in 63 (63.1%) eyes. Correspondingly, mean VA increased significantly (pConclusions: Gain in VA after intravitreal injection of 20–25 mg of triamcinolone acetonide is significantly and negatively correlated with preoperative VA. It is significantly larger in eyes with retinal pigment epithelium detachment than in eyes with minimally classic subfoveal neovascularisation.